Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierHôpital Haut-Lévêque [CHU Bordeaux]
dc.contributor.authorCÈBE, Amélie
hal.structure.identifierHôpital Haut-Lévêque [CHU Bordeaux]
dc.contributor.authorDESSANE, Bérangère
hal.structure.identifierHôpital Haut-Lévêque [CHU Bordeaux]
dc.contributor.authorGOHIER, Pauline
hal.structure.identifierHôpital Haut-Lévêque [CHU Bordeaux]
dc.contributor.authorBERNADOU, Jean-Marc
dc.contributor.authorVENET, Arnaud
hal.structure.identifierBiologie des maladies cardiovasculaires = Biology of Cardiovascular Diseases
dc.contributor.authorXUEREB, Fabien
hal.structure.identifierCentre Hospitalier Universitaire d'Angers [CHU Angers]
dc.contributor.authorCRAUSTE-MANCIET, Sylvie
dc.date.accessioned2023-05-11T12:51:43Z
dc.date.available2023-05-11T12:51:43Z
dc.date.issued2023-03-10
dc.identifier.issn1999-4923en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/180988
dc.description.abstractEnIn the context of essential drug shortages, this article reports a proof of concept for the hospital preparation of a 2% propofol injectable nanoemulsion. Two processes for propofol were assessed: mixing propofol with the commercial Intralipid 20% emulsion and a "de novo" process performed using separate raw materials (i.e., oil, water, and surfactant) and optimized for droplet size reduction with a high-pressure homogenizer. A propofol HPLC-UV stability-indicating method was developed for process validation and short-term stability. In addition, free propofol in the aqueous phase was quantified by dialysis. To envision routine production, sterility and endotoxin tests were validated. Only the "de novo" process using high-pressure homogenization gave satisfactory physical results similar to commercialized Diprivan 2%. Both terminal heat sterilization processes (121 °C, 15 min and 0.22 µm filtration) were validated, but an additional pH adjustment was required prior to heat sterilization. The propofol nanoemulsion was monodisperse with a 160 nm mean droplet size, and no droplets were larger than 5µm. We confirmed that free propofol in the aqueous phase of the emulsion was similar to Diprivan 2%, and the chemical stability of propofol was validated. In conclusion, the proof of concept for the in-house 2% propofol nanoemulsion preparation was successfully demonstrated, opening the field for the possible production of the nanoemulsion in hospital pharmacies.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectArticle clinique
dc.title.enHospital Production of Sterile 2% Propofol Nanoemulsion: Proof of Concept.
dc.title.alternativePharmaceuticsen_US
dc.typeArticle de revueen_US
dc.subject.halSciences du Vivant [q-bio]/Médecine humaine et pathologieen_US
dc.identifier.pubmed36986768en_US
bordeaux.journalPharmaceuticsen_US
bordeaux.volume15en_US
bordeaux.hal.laboratoriesBiologie des maladies cardiovasculaires (BMC) - UMR 1034en_US
bordeaux.issue3en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.identifierhal-04095042
hal.version1
hal.date.transferred2023-05-11T12:51:46Z
hal.exporttrue
workflow.import.sourcepubmed
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Pharmaceutics&rft.date=2023-03-10&rft.volume=15&rft.issue=3&rft.eissn=1999-4923&rft.issn=1999-4923&rft.au=C%C3%88BE,%20Am%C3%A9lie&DESSANE,%20B%C3%A9rang%C3%A8re&GOHIER,%20Pauline&BERNADOU,%20Jean-Marc&VENET,%20Arnaud&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée